Our goal is to meaningfully improve people’s lives by learning from the wisdom of their adaptive immune systems. It’s a bold objective that we’re uniquely built to achieve.
-
Every immune system
has a story to tell.At Adaptive, we’re writing the next chapter of precision health —
powered by immune-driven medicine.
The key is knowing how to listen.
-
Adaptive and Genentech, a member
of the Roche Group, partner on the
next generation of cell therapyLearn more
*The completion of the agreement is subject to customary closing conditions, including clearance
under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to occur in the
first quarter of 2019. -
Medicare now covers the FDA-cleared
clonoSEQ® Assay for patients
with multiple myeloma and B-cell ALL
Coverage available for testing performed on bone marrow samples
at time points throughout a patient’s treatmentLearn moreclonoSEQ is an FDA-cleared in vitro diagnostic (IVD) test service for use in B-cell ALL and multiple myeloma
patients to detect and monitor measurable residual disease (MRD) in bone marrow samples. clonoSEQ is also
available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service.
clonoSEQ is available by prescription only. For important information about the FDA-cleared uses of clonoSEQ,
including test limitations, visit clonoSEQ.com/technical-summary.
Keep up to date with Adaptive.